Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 12/20 | 0.39 |
| ▸ | RET | P07949 | 3/20 | 0.38 |
| ▸ | ESR1 | P03372 | 2/20 | 0.38 |
| ▸ | PIM2 | Q9P1W9 | 4/20 | 0.38 |
| ▸ | AXL | P30530 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | FYN | P06241 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16083391 | 0.89 | PIM1 (0.40) | PIM1RETPIM2AXL | |
| SCHEMBL15261465 | 0.80 | PIM1 (0.44) | PIM1RETPIM2 | |
| SCHEMBL860204 | 0.80 | PIM1 (0.37) | PIM1RETESR1PIM2 | |
| SCHEMBL15261632 | 0.79 | PIM1 (0.45) | PIM1RETPIM2 | |
| SCHEMBL20967402 | 0.79 | TGFBR2 (0.49) | PIM1RETPIM2AXLGSK3B | |
| SCHEMBL15891411 | 0.78 | RET (0.53) | PIM1RETPIM2 | |
| SCHEMBL15891337 | 0.78 | PIM1 (0.61) | PIM1RETPIM2 | |
| SCHEMBL16083665 | 0.78 | PCSK9 (0.49) | RET | |
| SCHEMBL15261764 | 0.78 | PIM1 (0.44) | PIM1RETPIM2FYN | |
| SCHEMBL31462309 | 0.76 | RET (0.60) | PIM1RETPIM2GSK3BFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160024114-A1 | MACROCYCLIC RIP2 KINASE INHIBITORS | ONCODESIGN S.A. (FR) | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024114-A1 | MACROCYCLIC RIP2 KINASE INHIBITORS | RIPK2, RIPK1, RIPK3 | PIM1 329/4885RET 280/4885ESR1 3618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.